Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1,105	1,004	781.37	396.59	75.42	66.56
Revenue Growth	42.46%	28.46%	97.02%	425.83%	13.31%	-73.44%
Cost of Revenue	394.82	398.09	445.29	412.9	392.87	426.07
Gross Profit	710.47	605.69	336.07	-16.31	-317.45	-359.51
Selling, General & Admin	545.24	550.27	501.05	500.82	277.16	176.77
Operating Expenses	545.24	550.27	501.05	500.82	277.16	176.77
Operating Income	165.22	55.43	-164.98	-517.12	-594.61	-536.28
Interest Expense	-43.6	-44.33	-40.39	-29.58	-32.63	-13.24
Interest & Investment Income	13.4	13.14	12.77	20.93	8.91	0.42
Other Non Operating Income (Expenses)	0.12	-0.13	-2.17	-0.73	-0.29	-96.31
EBT Excluding Unusual Items	135.15	24.11	-194.77	-526.5	-618.61	-645.41
Other Unusual Items	-	-	-1.95	-	-32.89	-100.59
Pretax Income	135.15	24.11	-196.72	-526.5	-651.5	-746
Income Tax Expense	1.88	1.72	1.16	2.13	0.67	0.35
Net Income	133.27	22.39	-197.88	-528.63	-652.17	-746.35
Net Income to Common	133.27	22.39	-197.88	-528.63	-652.17	-746.35
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	127	126	124	119	106	84
Shares Outstanding (Diluted)	131	130	124	119	106	84
Shares Change	5.48%	4.80%	4.40%	11.84%	25.70%	12.32%
EPS (Basic)	1.05	0.18	-1.60	-4.45	-6.15	-8.84
EPS (Diluted)	1.03	0.17	-1.60	-4.45	-6.15	-8.84
EPS Growth	-	-	-	-	-	-
Free Cash Flow	37.47	45.01	-88.27	-595.51	-515.27	-564.23
Free Cash Flow Per Share	0.28	0.35	-0.71	-5.02	-4.86	-6.68
Gross Margin	64.28%	60.34%	43.01%	-4.11%	-	-
Operating Margin	14.95%	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Profit Margin	12.06%	2.23%	-25.32%	-133.29%	-864.70%	-1121.28%
Free Cash Flow Margin	3.39%	4.48%	-11.30%	-150.16%	-683.18%	-847.66%
EBITDA	166.63	56.99	-163.18	-515.34	-593.06	-534.9
EBITDA Margin	15.07%	5.68%	-20.88%	-129.94%	-	-
D&A For EBITDA	1.4	1.56	1.8	1.78	1.55	1.38
EBIT	165.22	55.43	-164.98	-517.12	-594.61	-536.28
EBIT Margin	14.95%	5.52%	-21.11%	-130.39%	-	-
Effective Tax Rate	1.39%	7.14%	-	-	-	-
Revenue as Reported	1,105	1,004	781.37	396.59	75.42	66.56

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error